Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 281

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Blood (2024) 144 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2024-197898

Published: 2024

Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Blood (2024) 144 (Supplement 1): 658.

https://doi.org/10.1182/blood-2024-200925

Published: 2024

Journal Articles

Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Swe Mar Linn, Nihar Desai, Steven M. Chan, Andre C. Schuh, Aniket Banker, Marta Beata Davidson, Guillaume Richard-Carpentier, Aron Shimmer, Dawn C. Maze, Karen Yee, Mark D. Minden, Vikas Gupta, Tracy Stockley, Hassan Sibai, Jose-Mario Capo-Chichi, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 1570.

https://doi.org/10.1182/blood-2024-211434

Published: 2024

Journal Articles

Odyssey: A Phase 2 Open-Label Study of Momelotinib in Combination with Luspatercept in Patients with Transfusion-Dependent Myelofibrosis

Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bryan Strouse, Bharat Patel, Catherine Ellis, Claire Harrison

Blood (2024) 144 (Supplement 1): 3191.2.

https://doi.org/10.1182/blood-2024-205767

Published: 2024

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Akhil Rajendra, Elliot Smith, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Maria Agustina Perusini, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 5193.

https://doi.org/10.1182/blood-2024-208884

Published: 2024

Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2024-193193

Published: 2024

Journal Articles

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Eshrak Al-Shaibani, Marta Beata Davidson, Aniket Bankar, Steven M. Chan, Hassan Sibai, Dawn C. Maze, Aaron D Schimmer, Mark D. Minden, Karen Yee, Vikas Gupta, Andre C. Schuh, Guillaume Richard-Carpentier

Blood (2024) 144 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2024-209476

Published: 2024

Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Blood (2024) 144 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2024-204004

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Vikas Gupta, Yizhe Chen, Patrick Brown, Danny Jeyaraju, Moshe Talpaz, Ruben Mesa, Richard Pilot, Christopher Hernandez, Jia Wang, Jean-Jacques Kiladjian, Alessandro Vannucchi, Claire Harrison

Blood (2024) 144 (Supplement 1): 6623.

https://doi.org/10.1182/blood-2024-194223

Published: 2024

Journal Articles

Clinical Relevance of NPM1 Quantitative PCR As Standard of Care with Different Cut-Off Values on Treatment Outcomes in NPM1-Mutated Acute Myeloid Leukemia Patients

Donna Zhe Sian Eng, Andre C. Schuh, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Hassan Sibai, Dawn C. Maze, Karen Yee, Aaron D Schimmer, Vikas Gupta, Tracy Stockley, Jose-Mario Capo-Chichi, Chen Steven, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 6172.

https://doi.org/10.1182/blood-2024-211783

Published: 2024

Journal Articles

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Elliot Smith, Akhil Rajendra Kurup, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 1483.

https://doi.org/10.1182/blood-2024-202069

Published: 2024

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Guillaume Richard-Carpentier, Gopila Gupta, Charina Cameron, Severine Cathelin, Aniket Bankar, Marta Beata Davidson, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Tracy Murphy, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Joseph Brandwein, Caroline Jane McNamara, Steven M. Chan

Blood (2023) 142 (Supplement 1): 159.

https://doi.org/10.1182/blood-2023-188341

Published: 2023

Journal Articles

Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data

Ruben Mesa, Vikas Gupta, John Mascarenhas, Gabriella Hobbs, Jean-Jacques Kiladjian, Giacomo Coltro, Vincenzo Bagnardi, Chiara Oriecuia, Lennart Kann, Gozde Colak, Claire N Harrison, Debarshi Dey

Blood (2023) 142 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2023-179924

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Dawn C. Maze, Karen Yee, Mark D. Minden, Steven M. Chan, Jonas Mattsson, Rajat Kumar, Vikas Gupta, Jose-Mario Capo-Chichi, Tracy Stockley, Hassan Sibai, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2023-190694

Published: 2023

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

NARROW

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Odyssey: A Phase 2 Open-Label Study of Momelotinib in Combination with Luspatercept in Patients with Transfusion-Dependent Myelofibrosis

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Clinical Relevance of NPM1 Quantitative PCR As Standard of Care with Different Cut-Off Values on Treatment Outcomes in NPM1-Mutated Acute Myeloid Leukemia Patients

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only